Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma

A. Dodero; A. Guidetti; A. Tucci; F. Barretta; M. Novo; L. Devizzi; A. Re; A. Passi; A. Pellegrinelli; G. Pruneri; R. Miceli; A. Testi; M. Pennisi; M. C. Di Chio; P. Matteucci; C. Carniti; F. Facchetti; G. Rossi; P. Corradini

doi:10.1038/s41375-018-0320-9

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma

A. Dodero, A. Guidetti, A. Tucci, F. Barretta, M. Novo, L. Devizzi, A. Re, A. Passi, A. Pellegrinelli, G. Pruneri, R. Miceli, A. Testi, M. Pennisi, M. C. Di Chio, P. Matteucci, C. Carniti, F. Facchetti, G. Rossi, P. Corradini

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1047-1051
Number of pages	5
Journal	Leukemia
Volume	33
Issue number	4
DOIs	https://doi.org/10.1038/s41375-018-0320-9
Publication status	Published - Apr 1 2019

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-018-0320-9

Cite this

Dodero, A., Guidetti, A., Tucci, A., Barretta, F., Novo, M., Devizzi, L., Re, A., Passi, A., Pellegrinelli, A., Pruneri, G., Miceli, R., Testi, A., Pennisi, M., Di Chio, M. C., Matteucci, P., Carniti, C., Facchetti, F., Rossi, G., & Corradini, P. (2019). Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia, 33(4), 1047-1051. https://doi.org/10.1038/s41375-018-0320-9

Dodero, A , Guidetti, A, Tucci, A, Barretta, F, Novo, M, Devizzi, L, Re, A, Passi, A, Pellegrinelli, A, Pruneri, G , Miceli, R, Testi, A, Pennisi, M, Di Chio, MC, Matteucci, P , Carniti, C , Facchetti, F, Rossi, G & Corradini, P 2019, 'Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma', Leukemia, vol. 33, no. 4, pp. 1047-1051. https://doi.org/10.1038/s41375-018-0320-9

@article{7919ad95a1624c8fb5225d745a2d0112,

title = "Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma",

author = "A. Dodero and A. Guidetti and A. Tucci and F. Barretta and M. Novo and L. Devizzi and A. Re and A. Passi and A. Pellegrinelli and G. Pruneri and R. Miceli and A. Testi and M. Pennisi and {Di Chio}, {M. C.} and P. Matteucci and C. Carniti and F. Facchetti and G. Rossi and P. Corradini",

year = "2019",

month = apr,

day = "1",

doi = "10.1038/s41375-018-0320-9",

language = "English",

volume = "33",

pages = "1047--1051",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma

AU - Dodero, A.

AU - Guidetti, A.

AU - Tucci, A.

AU - Barretta, F.

AU - Novo, M.

AU - Devizzi, L.

AU - Re, A.

AU - Passi, A.

AU - Pellegrinelli, A.

AU - Pruneri, G.

AU - Miceli, R.

AU - Testi, A.

AU - Pennisi, M.

AU - Di Chio, M. C.

AU - Matteucci, P.

AU - Carniti, C.

AU - Facchetti, F.

AU - Rossi, G.

AU - Corradini, P.

PY - 2019/4/1

Y1 - 2019/4/1

UR - http://www.scopus.com/inward/record.url?scp=85059843737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059843737&partnerID=8YFLogxK

U2 - 10.1038/s41375-018-0320-9

DO - 10.1038/s41375-018-0320-9

M3 - Letter

C2 - 30631117

AN - SCOPUS:85059843737

SN - 0887-6924

VL - 33

SP - 1047

EP - 1051

JO - Leukemia

JF - Leukemia

IS - 4

ER -

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this